Skip to content
Webe Honey – Lifestyle
Author:
Unicycive Therapeutics, Inc.
Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
November 16, 2026
Unicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
November 4, 2026
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027
October 21, 2026
Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
October 1, 2026
Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
September 29, 2026
Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 1, 2026
Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026
Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)
June 30, 2026